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Urinary tract infections (UTIs) are a medical threat with the high morbidity of 150 
million people worldwide a year. UTIs like other infections are treated with the broad-
spectrum antibiotics which consequently leads to the increase of resistances and the 
conventional method for the diagnosis of urinary tract infections takes 48-72h for the 
identification of the bacteria and antimicrobial susceptibility testing (AST) results to be 
available to the physicians. Hence the rapid AST would increase the adequate choice of 
antibiotics for the better outcome of the patients. Therefore, our study aimed to demonstrate 
that AST can be performed directly on urine samples using the disk diffusion method within 
8 hr’ incubation. 
A total of 103 urine samples containing ≥ 2.104 bacterial/ml and monobacterial 
(Enterobacteriaceae) after gram staining was tested using disk diffusion method with 8 hr’ 
incubation. And the results were compared to the standardized VITEK-2 AST.  We 
compared the categorical agreements and the correlation between both methods. 
Over the 1545 tested drug combinations in all isolates studied, the overall categorical 
agreement of the direct rapid disk diffusion and the standardized susceptibility testing using 
VITEK-2 was 92.9%, with 4.9% minor errors, 0.9% major error 1.2% very major errors. 
Our results showed an excellent categorical agreement and correlations between diameters 
for dRAST and VITEK-2 susceptibility. The direct rapid AST on urine containing 
monobacterial Enterobacteriaceae can predict the reliable result of AST within 8 hr. The 






Urinary tract infections (UTIs) are a medical threat with the high morbidity of 
150 million people worldwide a year [1]. Among the bacteria and fungi causing UTIs 
Enterobacteriaceae is the most common [2]. Especially, Escherichia coli cause 80% of 
the uncomplicated UTI [3]. UTIs like other infections are treated with broad spectrum 
antibiotics which consequently leads to the increase of resistance. Hence the rapid AST 
would increase the adequate choice of antibiotics for the better outcome of the patients 
[4]. Disk diffusion (standard method) and commercial broth microdilution kits are widely 
used for antimicrobial susceptibility testing in many clinical settings [5]. The commercial 
kit requires much time and effort to perform, and it is expensive as well [6]. 
To ensure accurate and timely antimicrobial therapy we need rapid methods for 
identification since it takes  2 to 3 days for the conventional method from the time of sample 
collection till the time when the results are available to the physician [7]. Many other 
methods which are reliable for rapid AST have been developed such as Vitek Classic 
(bioMe´rieux, Marcy L’E`toile, France), the more automated VITEK 2 (bioMe´rieux) and 
Microscan Walkaway (Dade-Behring Microscan, Sacramento, CA, USA), and Phoenix 
system (BD Diagnostic Systems, Sparks, MD,USA) [8]. 
Despite the reliability and fastness of results from these methods, many 
laboratories from low-income settings cannot afford due to their high cost [9]. Currently 
EUCAST published a guideline for rapid AST in blood using disk diffusion methods.  But, 
neither EUCAST nor CLSI has approved yet the guideline for rapid AST in the urine.                                                                                                                       
Many papers on reducing the turnaround time of antimicrobial susceptibility testing have 
been published [10]. However, limited studies have been done on short incubation time of 
8hr  using disk diffusion directly on urine samples. 
Our study aimed at evaluating the performance of direct rapid disk diffusion AST 
on urine samples within 8 hr’ incubation with the standard antimicrobial susceptibility 
testing by VITEK2 using CLSI AST breakpoints. 
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II. LITERATURE REVIEW 
 
Urinary tract infections are a public health concern in all age groups of men and 
women by which annually encounters 7 million office visits and more than 1 million 
emergency visits along with 100, 000 hospitalizations [11]. Compared to males, females 
are more exposed to urinary tract infections which is explained by 40 to 50% of women 
experience at least one UTI during their lifetime [1]. Bacterial identification and 
antimicrobial susceptibility testing results on routine analysis take normally 2 to 3 days, 
where most of the laboratories use disc diffusion test, E-test and broth dilution using 
microtitration plates for antimicrobial susceptibility testing [12]. 
In a time of increasing antimicrobial resistance, an inexpensive method that will 
shorten the turn around time of identification and antimicrobial susceptibility testing of 
pathogens responsible for urinary tract infections would play an important role in proper 
and timely antimicrobial therapy [3, 7]. The high usage of unnecessary antibiotics in 
urinary tract infections has led to the emergence of resistance which is not only a problem 
among nosocomial and complicated UTIs but also in community-acquired, simple UTIs 
[11]. In the USA during the year 2014 more than 266 million antimicrobial prescriptions 
provided, 30% of them were given unnecessarily [2]. Rapid sensitivity test directly on urine 
is reliable in monobacterial gram-negative infections and it is useful in the proper 
management of UTI and reduces the use of broad-spectrum antimicrobials [1]. 
A rapid diagnostic method provides the real image of patients prior to the treatment 
with significant number of pathogens in urine to avoid the needless antibiotic therapy in 
patients with non-microbial urinary tract symptoms and helps in selecting the proper 
antibiotic for instance though 60% of E. coli strain in community maybe ampicillin-
resistant but patients found to have been infected by E. coli strain susceptible to ampicillin 





   Table 1. Clinical manifestation of urinary tract infections  [13] 
Type Clinical Manifestations 
Asymptomatic Patients do not present any local or systemic symptom referring to 
Symptomatic 1. Uncomplicated UTI 
a. Acute Cystis: dysuria, urinary frequency, and urgency. 
Nocturia, hesitancy, suprapubic discomfort. 
b. Acute Pyelonephritis: low-grade fever with or without 
lower-back. 
c.  Prostatitis for men only. 
2. Complicated UTI 
    Symptomatic episodes of cystis and pyelonephritis in men and 
women. 
 
Asymptomatic bacteriuria is commonly seen in elderly people and is characterized by the 
presence of a positive urine culture specimen, bacteria count of ≥ 105 CFU/ml (with or 
without pyuria) but with no signs or symptoms of infection. It does not necessitate 
antimicrobial therapy unless for the exceptional conditions [13, 14]. 
 
 2.1 incidence and antimicrobial resistance trends of urinary tract infections 
 
Globally we estimate 150 million urinary tract infections annually [15].  Around 
2007,  there was an estimation of 10.5 million office visits for UTI symptoms in which 
0.9% were outpatients and 2-3 million visits at the emergency in the USA [16]. Urinary 
tract infection is a common contagion among men and women but the incidence is quite 
high among women due to their physiology [17].  As the number of antimicrobials resistant 
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to outpatient therapies has risen, the number of hospitalizations for UTIs has increased also, 
Between 2000 and 2009,  hospitalizations for UTIs increased dramatically [18]. 
The indwelling of catheters in hospitalized patients due to comorbidities such as 
old age, diabetes, spinal cord injury, and urologic abnormalities usually leads to urinary 
tract infections [19]. UTIs are categorized in clinical settings as either uncomplicated or 
complicated whereby Uncomplicated UTIs affect the so-called healthy individuals with no 
remarkable structural or neurological urinary tract abnormalities [16].  E. coli is considered 
as the pathogen responsible for the most incidence of UTIs with 80-85% of the cases 
followed by Staphylococcus saprophyticus which occupies 5-10% [17]. Most of the times 
UTIs are not life-threatening by which its management only requires simple antibiotic 
therapy and the infection is limited to the lower urinary tract. However, recurrences are 
common and may evolve into an upper UTI (pyelonephritis) requiring a heavier antibiotic 
treatment and more extensive management [20]. 
The management of acute complicated UTI  by empirical antibiotics especially in 
women requires full comprehensive knowledge of current pathogens involving in most 
cases of infections and their drug susceptibility [21]. Patients with symptomatic UTI 
usually receive antibiotic therapy, which consequently can lead to multidrug-resistant 
strains due to the long-term disruption of the vagina and gastrointestinal normal flora [16]. 
The prescription of antibiotics in UTIs increases the risk of antibiotic resistance that persists 
for at least twelve months after therapy [22]. Different antibiotics such as nitrofurantoin 
monohydrate, trimethoprim-sulfamethoxazole, fosfomycin trometamol, pivmecillinam, 
fluoroquinolones, and beta-lactams are recommended by international guidelines for the 
management of uncomplicated UTIs and pyelonephritis [23]. The growing of CTX-M 
ESBLs in E. coli, as well as Klebsiella species in the community, have made the 
management of UTI became complicated. Differently to before 2003 when most of the 






The UTI caused by ESBL–producing Enterobacteriaceae is common in all health 
facilities mostly E. coli. Therefore, before selecting the antibiotic prior to the treatment of 
the known pathogen, the activity of the drug and duration of therapy must be taken into 
consideration as the antimicrobial resistance differs depending on the continent, country or 
institution [25]. The increase of E. coli in hospitalized patients and in fecal carriage among 
healthy people in France is leading to the high antimicrobial resistance prevalence in 
urinary tract infections [26]. The pathogens responsible for Urinary tract infections in 
Korea are proven to be higher resistant to trimethoprim-sulfamethoxazole (TMP-SMX) 
than those in the United States and Europe where this antibiotic is given as primary 
treatment for UTIs, it is in this regard that in Korea they recommend fluoroquinolones as a 
primary antibiotic for UTIs. However, the failure rate of fluoroquinolone treatments is high 
[27]. 
The study done in Switzerland on the analysis of E. coli in urinary samples 
collected from a university hospital between 1997 and 2007 showed the increasing trend in 
resistance to the following antibiotics trimethoprim-sulfamethoxazole, ciprofloxacin and 




























Figure 1. Main roots causes of antimicrobial resistance [29] 
 
The Antibiotics administration in many countries is not regulated whereby they are 
easily accessible by anyone over counters that are consequently overused unnecessarily 
[30]. The antibiotics prescribed in ICUs 30% to 60% of them are wrongly and needlessly 
given, which definitely play an important role in the development of problems caused by 
antimicrobial resistance, moreover, the epidemiological studies proved the association 
between the intake of antibiotics and the spreading of resistance in the hospitals and ICU 
[31]. The  hospital stay gets longer, delayed recovery and extensive disability and the public 
healthcare costs increase as well, whereby in 2013 the estimated health cost linked to 
antimicrobial resistance in the USA was 55 billion USD and every year they encountered 
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2 million people who were sick and 23,000 deaths cause of antimicrobial resistance 
infections [32]. 
 
2.2 Diagnosis for UTIs 
 
The diagnosis of UTI in medical settings like other bacterial infections depends on 
culturing the clinical sample which has the delay of two to three days from the time of 
collection up to the delivery of results, this delay is due to the time of sample transportation 
from ward to the laboratory and the time necessary for the bacteria to grow on a culture 
media for identification [33]. Despite the incidence of urinary tract infections, their 
diagnosis is complicated as well. For some UTIs exhibit, symptoms and others are 
asymptomatic thus require various diagnostic criteria for the Clinicians to be able to 
differentiate UTIs from other diseases [34]. 
Standard diagnostic examination for UTI begins with the presentation of clinical 
symptoms, which commonly include dysuria, urinary frequency, and urgency. Clinicians 
often order screening by colorimetric dipstick testing for nitrites and leukocyte esterase, 
which detect bacteriuria and pyuria, respectively. However, urine dipsticks can give false-
negative results in the case of non-nitrite-producing pathogens, such as Enterococcus and 
Staphylococcus species, or in dilute urine samples [35]. The midstream urine culture is 
necessary for the identification and detection of the pathogen and reveals the level of 
bacteriuria. However, neither medical laboratory nor any scientific paper has standardized 
the minimum level of bacteriuria signifying a urinary tract infection but many laboratories 







Table 2. Interpretation and tests of urine culture [37] 
Definitions Bacteria count Interpretation and tests 
Asymptomatic 
 
≤ 104 CFU/ml 
104-105 CFU/ml 
≥ 105 CFU/ml 
Probable Absence of UTI 
Repeat the Test (Request for the second 
Urine) 




≥ 105 CFU/ml 
Probable Absence of UTI 
Identification and AST 
Identification and AST 
 If more than two pathogens are present in 
the urine sample it is reported as probable 
contamination. 
 
Flow cytometry identifies samples that can be cultured from those that can be 
reported as negative without culture, having that urine is among the most processed sample 
in microbiological laboratories, it requires a method that can rapidly identify positive 
samples appropriate for direct ID and AST to shorten the time of results [38]. The clinical 
symptoms give a general indication of the infections but many infections don’t manifest 
any symptom or exhibit the same symptoms with others. Therefore, any patient suspected 
to have UTIs must be examined on a culture basis where we use semi-quantitative or 
quantitative cultures and their susceptibility to antimicrobial agents is determined which 
many resistant strains are associated with hospital-acquired infection and cause a serious 
infection of the urinary tract [39]. CLSI and EUCAST have set the breakpoints of 
antibiotics for the bacteria which serve in classification of bacteria to susceptible, 
intermediate or resistant and it helps clinicians to know the right antibiotic and dose to give 
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to the patient accordingly, however,  it is crucial to have both identification and AST for 
the proper antibiotic therapy [40]. 
 
2.3 Therapeutic options in UTIs 
 
Antibiotics such as fluoroquinolones, β-lactams, trimethoprim-sulfamethoxazole, 
and nitrofurantoin are generally used in clinical settings to treating UTI, however, the dose 
differs depending on the condition of the patients [41]. Due to the side effects caused by 
many antibiotics, clinicians should check on patients after 2 days since they have started 
the therapy and change the regimen for where it is necessary to reduce the risk of effects 
[42]. To ensure the effectiveness of oral antibiotics therapy in UTIs patients, they must 
have no renal malfunction to retain the minimum concentration capable of killing the 
pathogen. However, in multidrug resistance, intravenous medication is recommended  [43]. 
The longer antibiotic therapy  (≥7 days) has been proved to be effective in pyelonephritis 
or febrile UTI. However,  in cystis the shorter treatment is recommended [44]. 
In vitro experiment done has proved the combination of ESBL and β-lactamase 
inhibitors to be effective in infections caused by carbapenem-resistant Enterobacteriaceae. 
The ceftazidime combined with β-lactamase inhibitor avibactam has shown the potential 
in treating the ESBL and Carbapenemase-producing gram-negative bacilli [45]. Pathogens 
presenting resistance to amoxicillin and ampicillin are high, therefore, they are not 









Table 3. Antibiotic therapy in acute uncomplicated cystis [27] 
Antimicrobial agent                                      Regimen  Dosage Duration of Therapy (days) 
Fosfomycin 3 g, x1 1 
Ciprofloxacin 300 mg or 250 mg, x2 3 
Cefpodoxime proxetil 100 mg, x2 5 
Cefdinir 100 mg, x3 5 
Cefditoren pivoxil 100 mg, x3 3 
Cefcapene pivoxil 100 mg, x3 5 
Cefexime 400 mg, x1 3 
Nitrofurantoin 100 mg, x2 5 
Pivmecillinam 400 mg, x3 3 
Amoxicillin-Clavulanate 500 or 150 mg, x2 7 












Table 4. Treatment for acute pyelonephritis [46] 




Ciprofloxacin                                                 300 mg or 250 mg, x2                  7
Levofloxacin                                                    750 mg, x1                                    5
Where fluoroquinolone resistance is thought to exceed 10%, the initial long-acting dose 
of ceftriaxone (1g) is recommended. 
Trimethoprim-sulfamethoxazole                                             160/800 mg, x2                            14 
 
The resistance rate of antibiotics in vitro changes overtime differently from a place 
to another. Therefore, it is better to identify the individual predictors of resistance to help 
physicians in administering better empirical therapy [46]. In a study done from Korea 
showed that in uncomplicated cystitis, fluoroquinolones are the better option for empirical 
antibiotic therapy in regions where resistances are high [27]. To combatting bacterial 
infections a lot of remedies such as bacteriophages, immune stimulator, vaccine, 
antimicrobial peptides, antibodies, and lysine are being developed in addition to the former 
antibiotics for better management and control of the high resistance globally [29]. Despite 
the great role that antibiotics play in treating bacterial urinary tract infections, they cause 
serious side effects. For instance, nitrofurantoin may be the cause of respiratory distress 
and liver injury, and FDA has proved that the intake of fluoroquinolones may lead to 





III. MATERIALS AND METHODS 
 
3.1 Specimen collection 
 
The study was carried out in the clinical microbiology laboratory of Severance 
Hospital from August to November 2019. The first phase consisted of setting the quality 
control ranges (Table 5), using the culture-negative urine samples spiked with E. coli 
ATCC 25922 to different bacterial load.  The infected urine was processed by flow 
cytometry (Sysmex UF-1000i, TOA Medical Electronics, Kobe, Japan), to establish a cut-
off value of bacterial count to select samples for direct antimicrobial susceptibility testing. 
The second phase consisted of performing direct AST to every urine received in the clinical 
microbiology laboratory. The samples which fulfilled the inclusion criteria  (≥ 20,000 
bacteria/ml plus the presence of gram-negative bacteria on microscopy). 
 
 3.2 Sample processing 
 
103 Urine samples received in the microbiology laboratory contained ≥ 20,000 
bacterial cells/ml and monobacterial (gram-negative) after gram stain were processed 
immediately or kept at 4°C for no longer than 24 hours before testing. The control strain 
was E. coli ATCC 25922. 
 
3.3 Species identification 
 
The identification of all isolates included in our study was performed after the 
sufficient number of colonies on overnight incubated agar plates and it was determined 
using MALDI- TOF MS system, ASTA Micro IDSys (ASTA Inc., Suwon, Korea) 




 3.4 Direct susceptibility testing  
 
Direct susceptibility testing was done on infected urine for quality control as well 
as all urine specimens received in the laboratory fulfilling the criteria within the study 
period. For the quality control, infected urine samples with E. coli strain were diluted 100 
and 1000 fold to achieve the starting concentrations of 106 & 105 CFU/ml. 100 µl of the 
mixture was inoculated on the MHA plate using a spreader. Commercial antimicrobial 
disks (ampicillin, cefazolin, ertapenem, cefepime, cefotaxime, ceftazidime, cefoxitin, 
aztreonam, trimethoprim-sulfamethoxazole, amikacin, gentamicin, piperacillin-
tazobactam, tigecycline, ciprofloxacin, imipenem (Becton, Dickinson and Company, 
Sparks, MD, USA) were applied and pressed firmly into the agar surface with a sterile 
forceps. 
For the clinical samples, the volume suggested by EUCAST for direct rapid AST 
in blood [48]. Depending on plates size. Hence, 130 μL and 350 μL of sample were taken 
and spread on the 90 mm and 150 mm-diameter MHA using a rotator, respectively.  The 
commercial antibiotics were loaded by using disk dispenser and pressed firmly into agar 
surface using forceps. The plates were incubated at 35±1°C and read on the same day after 
8 hr of incubation. The images of inhibition zones were taken and recorded using a digital 
scanner (Giles scientific, DC, USA, bio-MIC vision analyzer). 
 
 3.5 Conventional urine culture, species identification and AST 
 
The urine sample was inoculated and spread on both blood agar and Mac Conkey 
agar plates using a wire loop. Plates were incubated at 35±1 °C overnight. The colonies on 
agar plate were counted and identified using MALDI- TOF MS system, ASTA Micro 
IDSys. A standardized 0.5 McFarland suspension was prepared and N224 VITEK® 2 cards 




3.6 Comparison of DST and conventional AST 
 
For comparison, the antimicrobial susceptibility testing of isolates from standard 
cultures was determined using VITEK-2.  E. coli ATCC 25922 was included for quality 
control. Interpretation of Susceptibility testing ( susceptible, intermediate, or resistant)  for 
each bacteria and antibiotic was done following the criteria of the Clinical and Laboratory 
Standards Institute [13], to compare the concordance of the two methods. 
Results from direct and standard tests were compared by testing the correlation coefficient 
r using the Pearson test analyzed by SPSS 25. And discrepancies were classified as very 
major errors (VME), major errors (ME), or minor errors (mE). A Very major error was a 
susceptible result by the direct method and a resistant result by the standard method. A 
Major error was a resistant result by the direct method and a susceptible result by the 
standard method. A minor error was any discrepancy involving an intermediate result. 
Samples were kept in freezer -70 °C for the testing of MIC by E-test (bioMe’rieux SA, 
Marcy-L’E’toile, France) retrospectively for the discrepancies (Major and very major 














IV.  RESULTS 
 
We have preselected 128 urine samples with Enterobacteriaceae during the study 
period and 103 were included as presented in Figure 2. They were distributed as 68 (66%) 
E. coli, 17 (16.5%) Klebsiella pneumonia, 5 (4.9%) Citrobacter freundii, 2 (1.9%) 
Citrobacter braaki, 2 (1.9%) Enterobacter cloacae, 2 (1.9%) Klebsiella ocytica, 2 (1.9%) 
Proteus vulgaris, 2 (1.9%) Enterobacter aerogenes, 1 (1%) Raoultella ornithinolytica, 1 
(1%) Proteus mirabilis, 1 (1%) Morganella morgani. 
Concerning 25 excluded, 17 had more than one bacteria, 8 exhibited poor growth after 8 
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Over the 1545 tested combinations in all isolates studied, the overall categorical 
agreement of the direct rapid disk diffusion and the standard susceptibility testing using 
VITEK-2 was 1436 (92.9%), with 76 (4.9%) minor errors, 14 (0.9%) major errors and 19 
(1.2%) very major errors (Table 6). minor errors were mainly reported in ciprofloxacin 15 
(14.6%), ceftazidime 13 (12.7%), cefoxitin 9 (8.7%). According to the result from the 
comparison between dRAST and VITEK-2 susceptibility, All Antibiotics used, have 
correlation coefficient r ≥ 0.90 except from piperacillin-tazobactam, amikacin, ertapenem, 
imipenem, cefepime, tigecycline which have 0.74, 0.79, 0.78, 0.59, 0.84, 0.58 
respectively. 
Concerning majors errors observed , 4 (3.9%) cefepime, 2 (1.9%) aztreonam, 2 
(1.9) cotrimoxazole, 1 (1%) amikacin, 1 (1%) cefotaxime, 1 (1%) gentamycin, 1 (1%) 
cefazolin, 1 (1%) ceftazidime, 1 (1%) tigecycline. Out of 19 VME observed 5 (4.9%) 
were due to tigecycline, 4 (3.9%) due to cefazolin, 3 (2.9%) due to piperacillin-
tazobactam, 2 (1.9%) due to cotrimoxazole, 2 (1.9%) due to imipenem 1 (1%) due to 
ampicillin,1 (1%) due to aztreonam, 1 (1%) due to ertapenem. For some of the 
discrepancies, inhibition zones were close to clinical breakpoints, where a slight 



































Abbreviations: SD: Standard deviation, FOX: cefoxitin, AMP: ampicillin, CIP: 
ciprofloxacin, TZP: piperacillin-tazobactam, AN: amikacin, ATM: aztreonam, CTX: 
Antibiotics 
DST Standard disk diffusion 
QC Range QC Range 
FOX 22-29 23-29 
AMP 18-24 15-22 
CIP 31-38 29-37 
TZP 27-33 24-30 
AN 25-31 19-26 
ATM 31-37 28-36 
CTX 32-38 29-35 
GM 24-29 19-26 
IPM 29-36 26-32 
MI 24-31 19-25 
FEP 32-39 31-37 
CZ 25-33 21-27 
SXT 24-33 23-29 
CAZ 28-35 25-32 
ETP 31-38 29-36 
TGC 23-30 20-27 
19 
 
cefotaxime, GM: gentamicin, IPM: imipenem, MI: minocycline, FEP: cefepime, CZ: 
cefazolin, SXT: trimethoprim-sulfamethoxazole, CAZ: ceftazidime, ETP: ertapenem, 
TGC:  tigecycline,  QC: Quality control. 





 ME  VME 
r 
n %  n %  n %  n % 
Cefoxitin 103 94 91.2  9 8.7  0 0  0 0 0.93 
Ampicillin 103 99 96.1  3 2.9  0 0  1 1 0.92 
Ciprofloxacin 103 88 85.4  15 14.6  0 0  0 0 0.92 
Piperacillin-
Tazobactam 
103 94 91.3  6 5.8  0 0  3 2.9 0.74 
Ertapenem 103 100 97.1  2 1.9  0 0  1 1 0.78 
Amikacin 103 101 98.1  1 1  1 1  0 0 0.79 
Aztreonam 103 95 92.2  5 4.8  2 1.9  1 1 0.90 
Cefotaxime 103 97 94.2  5 4.8  1 1  0 0 0.95 
Gentamycin 103 100 97.1  2 1.9  1 1  0 0 0.96 
Imipenem 103 95 92.2  6 5.8  0 0  2 1.9 0.59 
Cefepime 103 93 90.3  6 5.8  4 3.9  0 0 0.84 
Cefazolin 103 98 95.1  0 0  1 1  4 3.9 0.90 
Cotrimoxazole 103 98 95.1  1 1  2 1.9  2 1.9 0.92 
Ceftazidime 103 89 86.4  13 12.6  1 1  0 0 0.90 
Tigecycline 103 94 91.3  2 1.9  1 1  5 4.9 0.58 
TOTAL 1545 1435 92.9  76 4.9  14 0.9  19 1.2  
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Abbreviations: CA: Categorical agreement, ME: major error, VME: Very major error, r: 
correlation coefficient. 








S I R S I R  
Amikacin 101 1 1 103 0 0 2 
Ampicillin 12 3 88 12 0 91 4 
Aztreonam 65 5 33 67 0 36 6 
Ciprofloxacin 34 21 48 45 10 48 15 
Cefoxitin 77 3 23 70 8 25 9 
Cefepime 79 0 24 80 6 17 10 
Cefazolin 44 0 58 41 0 62 5 
Ceftazidime 61 14 26 69 1 33 14 
Ertapenem 100 2 1 98 1 4 3 
Gentamycin 75 1 27 75 1 27 3 
Imipenem 99 2 2 93 6 4 8 
Tazobactam-Piperacillin 91 8 4 86 8 9 9 
Cotrimoxazole 56 1 46 57 0 46 5 
Tigecycline 96 0 7 92 2 9 9 
Cefotaxime 50 6 47 54 3 46 6 
S: Susceptible, I: Intermediate, R: Resistance  
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FEP R S ME 12 R DST 
GM R S ME 32 R DST 
ATM R S ME 48 R DST 




IPM S R VME 1.0 S DST 
TGC S R VME 24 R Vitek-
2 
E. coli AN R S ME 4 S Vitek-
2 

















TGC S R VME 2 R Vitek-
2 
E. coli FEP R S ME 8 S Vitek-
2 
E. coli SXT R S ME ≥32 R DST 




 a. E. coli ATCC 2592 with 106 CFU/ml 
  






                                                                          c. Clinical E. coli isolate  


















The main purpose of this study was to evaluate the performance of rapid direct 
AST on urine compared to the standard method using VITEK-2. Our study showed 
excellent results compared to the susceptibility of VITEK-2. According to Jorgensen 
criteria the rates of VME and the combination of ME and mE should be < 3%, <7% 
respectively [50]. And for our study VME was 1.2% and the combination of ME and mE 
were 5.8%. The observed discrepancies between DST and VITEK-2 AST were compared 
using the results of MIC by E-test. Out of 26 discrepant strains, only 13 strains were 
available and tested. Therefore, in 16 combination drug tested, found that the correct 
method for 37.5% of the drug tested was DST and 62.5% for Vitek-2 (Table 8). When 
analyzed the concordance between both methods, the interpretations of AST results were 
done following the published breakpoints from CLSI, however, for tigecycline we used 
EUCAST breakpoint since there is no published breakpoint by CLSI for this antibiotic in 
Enterobacteriaceae. 
The agreement for each antibiotic exceeds 85% in all isolates studied. Most of the 
strains studied were resistant to ampicillin, cefazolin, ciprofloxacin, cefotaxime, 
trimethoprim-sulfamethoxazole (85.4, 56.3, 46.6, 45.6, 44.7%) respectively. Direct 
antimicrobial susceptibility testing of urine form UTI samples (≥ 2.104 bacteria/ml) showed 
that the most effective agents were amikacin (98.1%), ertapenem (97.1%), imipenem 
(96.1%), tigecycline (93.2%),  and piperacillin-tazobactam (88.3%). A great number of 
urine samples (16.5%) have been excluded from this study due to the mixed infection of 
more or equal than two Enterobacteriaceae. However, its susceptibility results would be 
still useful in choosing the better option of empirical treatment. In a study done by Perillaud 
et al, the DST was compared to the standard disk diffusion AST and the categorical 
agreement of 97.9%, 1.5% of minor errors, 0.3% ME, and 0.3% VME were found [51]. 
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Though the susceptibility of rapid method seems to be incomplete, the phenotypic 
result generated in a short period compared to the conventional method can help the 
physician give the appropriate empirical therapy [10].  On the other hand, the direct 
susceptibility testing gives the real image of population susceptibility to antibiotics for it is 
done on the whole sample rather than from a single colony, therefore, the results are likely 
to be clinically relevant [10]. Studies done on DST on urine have all proved the reliability 
of this method in gram-negative, however,  the errors in the case of polymicrobial are quite 
high. Thus, it is suggested to be done in monobacterial only [52]. The limitation of our 
study is the spectrum of test strain. We included only Enterobacteriaceae. DST is not 
reliable in polymicrobial urine samples, either. Further, bacteria that have slow growth 
capacity do not allow the reading of inhibition zone diameters after 8 hr of incubation.  
Multiple bacterial infections with similar colonies characteristics in a sample are also big 
huddle to this rapid method because though it is rare, discrimination of different isolates on 
a plate by its’ colonial morphology is not easy , thus it can make an error in inhibition zone 
diameter measure.  
In conclusion, despite some errors, DST on urine is reliable in Enterobacteriaceae. 
Furthermore, the overall agreement and errors rates were within the acceptable limits which 
gives it the credential to be adopted into routine microbiology laboratory workflow since it 
helps us to save more than 24 hr.  E. coli and K. pneumoniae  were the most predominant 
isolates in UTI with a prevalence of 66%, 16.5%, respectively. Resistant rates to ampicillin, 
cefazolin and ciprofloxacin were the highest in the tested strains, whereas amikacin, 
ertapenem, imipenem, tigecycline were found to be the most effective drugs. DST and 
standard AST methods almost give the same results. The rapid AST reports by using DST 
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